Treating premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer with tamoxifen plus 2 years of ovarian suppression after surgery offers better disease-free survival than tamoxifen alone.
The antidepressant duloxetine can ease joint pain in women diagnosed with early-stage, hormone-receptor-positive breast cancer who are taking an aromatase inhibitor.
Taking Arimidex for 3 years after 5 years of tamoxifen reduced the risk of the cancer coming back in women diagnosed with hormone-receptor-positive breast cancer.
Being older and having lower cognitive reserve levels may increase the risk of cognitive problems during and after chemotherapy.
A new study shows that Arimidex and Aromasin are equally good at reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
Research has confirmed that tamoxifen reduces breast cancer recurrence risk during the standard 5 years of treatment and that recurrence risk stays lower during the next 5 years after tamoxifen treatment ends.
Results from a third study show that the experimental targeted therapy medicine abemaciclib improved progression-free survival in postmenopausal women diagnosed with hormone-receptor-positive, HER2-negative, advanced-stage breast cancer.
A study suggests that women treated with hormonal therapy for breast cancer are more likely to develop diabetes compared to women not treated with hormonal therapy.
A study suggests that the Oncotype DX test can offer relevant information about cancer progression and 2-year survival rates for women diagnosed with de novo stage IV cancer.
Taking tamoxifen for 2 years after surgery offers long-term survival benefits for premenopausal women diagnosed with early-stage, estrogen-receptor-positive disease compared to no treatment after surgery.
Ten years of Femara offers more benefits than 5 years.
Two studies suggest that a low dose of the antidepressant medicine Paxil can lower the number and severity of hot flashes in some women.
Postmenopausal women at high risk for breast cancer who hadn't been diagnosed continued to get risk-reducing benefits for at least 11 years after they stopped taking Arimidex preventively.
Many women stop taking adjuvant hormonal therapy medicine earlier than prescribed by their doctors.
The U.S. Preventive Services Task Force has recommended that women with a high risk of breast cancer but who haven't been diagnosed be offered medicines that can lower that risk.
Premenopausal women diagnosed with early-stage, hormone-receptor-positive, HER2-negative breast cancer with a high risk of recurrence benefit the most from Aromasin plus ovarian suppression.
Concerns about fertility caused about 30% of younger women diagnosed with hormone-receptor-positive, early-stage breast cancer to skip or stop taking tamoxifen.
A small study has found that a telephone counseling program helped overweight postmenopausal women diagnosed with early-stage breast cancer who were taking Femara lose weight.
Side effects cause many women to stop taking hormonal therapy medicine earlier than prescribed a new study reports.
A study suggests that about 25% of women who are prescribed hormonal therapy to reduce the risk of recurrence after surgery either don't start taking the medicine or stop taking it early.
Another large study finds 10 years of tamoxifen are better than 5.
Results from the MONALEESA-7 trial show that adding Kisqali to hormonal therapy and ovarian suppression significantly improves overall survival in premenopausal women diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer.
A study has found that women diagnosed with early-stage, hormone-receptor-positive breast cancer with no prescription drug coverage were less likely to start hormonal therapy than women who had insurance coverage for prescription drugs.
ASCO has put out new guidelines on using biomarkers to make decisions about treatments after surgery for women diagnosed with early-stage invasive breast cancer.